{"id":64356,"date":"2025-02-05T12:01:49","date_gmt":"2025-02-05T12:01:49","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/02\/05\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/"},"modified":"2025-02-05T12:01:49","modified_gmt":"2025-02-05T12:01:49","slug":"medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/","title":{"rendered":"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025"},"content":{"rendered":"<div>\n<p align=\"justify\">TORONTO\u00a0and\u00a0HOUSTON, Feb.  05, 2025  (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the \u201cCompany\u201d) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The company will also host one-on-one meetings with investors during these events.<\/p>\n<p align=\"justify\"><strong>Oppenheimer Annual Healthcare Life Sciences Conference 2025<\/strong><br \/><strong>Format:<\/strong>\u00a0Presentation<br \/><strong>Date:<\/strong>\u00a0Tuesday, February 11, 2025, at 9:20 a.m. ET<br \/><strong>Webcast link:<\/strong> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ho4PjpcSCh6ZHuO-ZH8LNsAsMs5Esb3_gc37JoeHDMMOHERZNyJmPXnCmuJMnDusezkpkRZ2Z1PMTvkGu2VycmRLD8Xbp2mO9A5-Dn_4XOBJOtEPWzmOJbLnPqSuHLZiPTJjaraZxQLYCBMDXgSAUCEFKTnbkQ5Sg4gR0uUyBnM=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/wsw.com\/webcast\/oppenheimer39\/mdna\/2754560<\/a><\/p>\n<p align=\"justify\">Webcast and replay information for this event will be available on the investor relations section of Medicenna\u2019s website on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gWQMPCu_9GvhjoXlDR9calEMXPbxsdld8BWp2gszq8n6JBJjxdNz8MMgT8ItZ-BqCjS8zKbGLwQR8DsgQrwjvooPvu6dEGH_2UpJg7aOiMWAQ-rUm1Y_ECzFQygXaXT-DkOdB_xQfFwZtD0-hgP3VTRb5znDEt-biy10nBqO1c8=\" rel=\"nofollow\" target=\"_blank\" title=\"Events &amp; Presentations\">Events &amp; Presentations<\/a> page. The webcast replay will be available for 180 days following the event.<\/p>\n<p align=\"justify\"><strong>B. Riley Securities Precision Oncology &amp; Radiopharma Conference 2025<\/strong><br \/><strong>Format:<\/strong>\u00a0Fireside Chat<br \/><strong>Date:<\/strong>\u00a0Friday, February 28, 2025<br \/><strong>Location:<\/strong> New York City, NY<\/p>\n<p align=\"justify\"><strong>One-on-One Investor Meetings<\/strong><\/p>\n<p align=\"justify\">In addition to the presentations, Medicenna\u2019s management team will be available for one-on-one meetings with investors at both conferences. Investors interested in scheduling a meeting can contact their respective conference representatives or reach out to Medicenna\u2019s investor relations team at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D0I3QhOT_T0c6Qm1cYQrWjiiofI6y1p39yGBuj4QvJPg2seRZYlpmg_E1wihp6oVk_N8RzAiDoZRIPjfXu8pcg==\" rel=\"nofollow\" target=\"_blank\" title=\"ir@medicenna.com\">ir@medicenna.com<\/a>.<\/p>\n<p><strong>About Medicenna Therapeutics<\/strong><\/p>\n<p align=\"justify\">Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna\u2019s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. MDNA11 is being evaluated in the Phase 1\/2 ABILITY-1 Study (NCT05086692) as a monotherapy and in combination with pembrolizumab. Medicenna\u2019s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA\/EMA, respectively. Medicenna\u2019s early-stage high-affinity IL-2\u03b2 biased IL-2\/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna\u2019s early-stage BiSKITs&#x2122; (Bifunctional SuperKine ImmunoTherapies) and the T-MASK&#x2122; (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically \u201ccold\u201d tumors.<\/p>\n<p align=\"justify\">For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kjDmq-4GgfO-F4oFNRfVRiplPsE_WqpE1ER9reRu79PswPaOE4t5CDg728_MI_zk8iWz1z-BFUpShyl-h6SsOiPxl1OGK_wO6ezNR0aDHNo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.medicenna.com<\/u><\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KL4dz666QSpXQnelPJ1YUpFT2a8xeoD9aPv7w60qbORnSU1ifs2nFaQDgqcKxsoDioq2isaHY8ggmWPRqpa2KQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>Twitter<\/u><\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YsB7Ei5OG_H8ePevg2oKZqmsqb2rftZOnqrAuyVdOWAApBediYKASpKy3J31XxhJLyPC0ci1XG0KBGLM66JzYCSlmrmYq_NVaacgkffX1ITYTVmaEqO8Sg_FmcjMYp4QbuTlZWGNBZOEOyaLwXZfBg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpect\u201d, \u201cbelieve\u201d, \u201cseek\u201d, \u201cpotentially\u201d and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.<\/p>\n<p align=\"justify\">The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.<\/p>\n<p align=\"justify\">This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.<\/p>\n<p align=\"justify\"><strong>Investor Contact:<\/strong><\/p>\n<p align=\"justify\">Christina Cameron<br \/>Investor Relations<br \/>ir@medicenna.com<br \/>(647) 953-0673<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTNjY2MyZGUtMTdkOS00MWZlLTk3ZGQtMDljZmZkNThlN2U5LTExMzQwNTI=\/tiny\/Medicenna-Therapeutics-Corp-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO\u00a0and\u00a0HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the \u201cCompany\u201d) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The [&#8230;]\n","protected":false},"author":1,"featured_media":64357,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-64356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025\" \/>\n<meta property=\"og:description\" content=\"TORONTO\u00a0and\u00a0HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the \u201cCompany\u201d) (TSX: MDNA, OTCQX: M\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T12:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/02\/Medicenna-Therapeutics-Corp-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025\",\"datePublished\":\"2025-02-05T12:01:49+00:00\",\"dateModified\":\"2025-02-05T12:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\",\"name\":\"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-02-05T12:01:49+00:00\",\"dateModified\":\"2025-02-05T12:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/","og_locale":"en_US","og_type":"article","og_title":"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025","og_description":"TORONTO\u00a0and\u00a0HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) &#8212; Medicenna Therapeutics Corp. (\u201cMedicenna\u201d or the \u201cCompany\u201d) (TSX: MDNA, OTCQX: M","og_url":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-02-05T12:01:49+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/02\/Medicenna-Therapeutics-Corp-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025","datePublished":"2025-02-05T12:01:49+00:00","dateModified":"2025-02-05T12:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/"},"wordCount":733,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/","url":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/","name":"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-02-05T12:01:49+00:00","dateModified":"2025-02-05T12:01:49+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/medicenna-therapeutics-to-participate-in-two-healthcare-investor-conferences-in-february-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=64356"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64356\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/64357"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=64356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=64356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=64356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}